Efficacy and safety implications of molecular constructs of biological agents for rheumatoid arthritis

Biologics for rheumatoid arthritis: an overview of Cochrane reviews

(2017) Jasvinder A. Singh et al.   Sao Paulo Medical Journal

Efficacy and Safety of Certolizumab Pegol for Crohn’s Disease: A Systematic Review and Meta-Analysis

(2013) Wei Da et al.   ADVANCES IN THERAPY

A phase 2 dose-ranging study of subcutaneous tabalumab for the treatment of patients with active rheumatoid arthritis and an inadequate response to methotrexate

(2013) Mark C Genovese et al.   ANNALS OF THE RHEUMATIC DISEASES

Novel targeted therapies: the future of rheumatoid arthritis? Mavrilumab and tabalumab as examples

(2013) Bernard Combe et al.   ANNALS OF THE RHEUMATIC DISEASES

Head-to-head comparison of subcutaneous abatacept versus adalimumab for rheumatoid arthritis: two-year efficacy and safety findings from AMPLE trial

(2013) Michael Schiff et al.   ANNALS OF THE RHEUMATIC DISEASES

A randomised, double-blind, parallel-group study of the safety and efficacy of subcutaneous tocilizumab versus intravenous tocilizumab in combination with traditional disease-modifying antirheumatic drugs in patients with moderate to severe rheumatoid arthritis (SUMMACTA study)

(2013) Gerd R Burmester et al.   ANNALS OF THE RHEUMATIC DISEASES

Performance of the 2010 ACR/EULAR classification criteria for rheumatoid arthritis: a systematic literature review

(2013) Helga Radner et al.   ANNALS OF THE RHEUMATIC DISEASES

EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs: 2013 update

(2013) Josef S Smolen et al.   ANNALS OF THE RHEUMATIC DISEASES

Tabalumab in Rheumatoid Arthritis Patients With an Inadequate Response to Methotrexate and Naive to Biologic Therapy: A Phase II, Randomized, Placebo-Controlled Trial

(2013) M. C. Genovese et al.   ARTHRITIS AND RHEUMATISM

P2X7Blockade Attenuates Murine Lupus Nephritis by Inhibiting Activation of the NLRP3/ASC/Caspase 1 Pathway

(2013) Jijun Zhao et al.   ARTHRITIS AND RHEUMATISM

The effectiveness of tofacitinib, a novel Janus kinase inhibitor, in the treatment of rheumatoid arthritis: a systematic review and meta-analysis

(2013) Paweł Kawalec et al.   CLINICAL RHEUMATOLOGY

The BAFF/APRIL system: Emerging functions beyond B cell biology and autoimmunity

(2013) Fabien B. Vincent et al.   CYTOKINE & GROWTH FACTOR REVIEWS

Targeting Interleukin-6 in Rheumatoid Arthritis

(2013) Md Yuzaiful Md Yusof et al.   DRUGS

Subcutaneous Golimumab Induces Clinical Response and Remission in Patients With Moderate-to-Severe Ulcerative Colitis

(2013) William J. Sandborn et al.   GASTROENTEROLOGY

Efficacy and Safety of Belimumab in Patients with Rheumatoid Arthritis: A Phase II, Randomized, Double-blind, Placebo-controlled, Dose-ranging Study

(2013) W. Stohl et al.   JOURNAL OF RHEUMATOLOGY

Subcutaneously Administered Ofatumumab in Rheumatoid Arthritis: A Phase I/II Study of Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics

(2013) R. Kurrasch et al.   JOURNAL OF RHEUMATOLOGY

Tocilizumab monotherapy versus adalimumab monotherapy for treatment of rheumatoid arthritis (ADACTA): a randomised, double-blind, controlled phase 4 trial

(2013) Cem Gabay et al.   LANCET

Serum rituximab levels and efficiency of B cell depletion: differences between patients with rheumatoid arthritis and systemic lupus erythematosus

(2013) V. Reddy et al.   RHEUMATOLOGY

Subcutaneous abatacept for the treatment of rheumatoid arthritis

(2013) Michael Schiff   RHEUMATOLOGY

A phase Ib multiple ascending dose study evaluating safety, pharmacokinetics, and early clinical response of brodalumab, a human anti-IL-17R antibody, in methotrexate-resistant rheumatoid arthritis

(2013) David A Martin et al.   ARTHRITIS RESEARCH & THERAPY

Safety and efficacy of ocrelizumab in combination with methotrexate in MTX-naive subjects with rheumatoid arthritis: the phase III FILM trial

(2012) William Stohl et al.   ANNALS OF THE RHEUMATIC DISEASES

The role of biosimilars in the treatment of rheumatic diseases

(2012) Thomas Dörner et al.   ANNALS OF THE RHEUMATIC DISEASES

Tabalumab, an anti-BAFF monoclonal antibody, in patients with active rheumatoid arthritis with an inadequate response to TNF inhibitors

(2012) Mark C Genovese et al.   ANNALS OF THE RHEUMATIC DISEASES

Long-term safety of rituximab in rheumatoid arthritis: 9.5-year follow-up of the global clinical trial programme with a focus on adverse events of interest in RA patients

(2012) Ronald F van Vollenhoven et al.   ANNALS OF THE RHEUMATIC DISEASES

The immunogenicity of anti-TNF therapy in immune-mediated inflammatory diseases: a systematic review of the literature with a meta-analysis

(2012) Sandra Garcês et al.   ANNALS OF THE RHEUMATIC DISEASES

Consensus statement on blocking the effects of interleukin-6 and in particular by interleukin-6 receptor inhibition in rheumatoid arthritis and other inflammatory conditions

(2012) Josef S Smolen et al.   ANNALS OF THE RHEUMATIC DISEASES

Efficacy and safety of mavrilimumab in subjects with rheumatoid arthritis

(2012) Gerd R Burmester et al.   ANNALS OF THE RHEUMATIC DISEASES

Rates of malignancy associated with juvenile idiopathic arthritis and its treatment

(2012) Timothy Beukelman et al.   ARTHRITIS AND RHEUMATISM

Head-to-head comparison of subcutaneous abatacept versus adalimumab for rheumatoid arthritis: Findings of a phase IIIb, multinational, prospective, randomized study

(2012) Michael E. Weinblatt et al.   ARTHRITIS AND RHEUMATISM

Placental Transfer of Anti–Tumor Necrosis Factor Agents in Pregnant Patients With Inflammatory Bowel Disease

(2012) Uma Mahadevan et al.   Clinical Gastroenterology and Hepatology

Belimumab – an anti-BLyS human monoclonal antibody for rheumatoid arthritis

(2012) Xingzhong Jin et al.   EXPERT OPINION ON BIOLOGICAL THERAPY

Anti–Interleukin-17 Monoclonal Antibody Ixekizumab in Chronic Plaque Psoriasis

(2012) Craig Leonardi et al.   NEW ENGLAND JOURNAL OF MEDICINE

Tofacitinib or Adalimumab versus Placebo in Rheumatoid Arthritis

(2012) Ronald F. van Vollenhoven et al.   NEW ENGLAND JOURNAL OF MEDICINE

Systematic Review and Meta-Analysis of the Efficacy and Safety of Existing TNF Blocking Agents in Treatment of Rheumatoid Arthritis

(2012) Kalle J. Aaltonen et al.   PLoS One

Cancer Risk of Anti-TNF-α at Recommended Doses in Adult Rheumatoid Arthritis: A Meta-Analysis with Intention to Treat and per Protocol Analyses

(2012) Guillaume Moulis et al.   PLoS One

2012 Update of the 2008 American College of Rheumatology recommendations for the use of disease-modifying antirheumatic drugs and biologic agents in the treatment of rheumatoid arthritis

(2012) Jasvinder A. Singh et al.   ARTHRITIS CARE & RESEARCH

Biologic Differences Between Various Inhibitors of the BLyS/BAFF Pathway: Should We Expect Differences Between Belimumab and Other Inhibitors in Development?

(2012) William Stohl   Current Rheumatology Reports

Ofatumumab, a fully human anti-CD20 monoclonal antibody, in biological-naive, rheumatoid arthritis patients with an inadequate response to methotrexate: a randomised, double-blind, placebo-controlled clinical trial

(2011) P. C. Taylor et al.   ANNALS OF THE RHEUMATIC DISEASES

Subcutaneous abatacept versus intravenous abatacept: A phase IIIb noninferiority study in patients with an inadequate response to methotrexate

(2011) M. C. Genovese et al.   ARTHRITIS AND RHEUMATISM

Atacicept in patients with rheumatoid arthritis and an inadequate response to methotrexate: Results of a phase II, randomized, placebo-controlled trial

(2011) R. F. van Vollenhoven et al.   ARTHRITIS AND RHEUMATISM

Atacicept in patients with rheumatoid arthritis and an inadequate response to tumor necrosis factor antagonist therapy: Results of a phase II, randomized, placebo-controlled, dose-finding trial

(2011) M. C. Genovese et al.   ARTHRITIS AND RHEUMATISM

A phase III, randomized, placebo-controlled study of belimumab, a monoclonal antibody that inhibits B lymphocyte stimulator, in patients with systemic lupus erythematosus

(2011) Richard Furie et al.   ARTHRITIS AND RHEUMATISM

Phase IIb dose-ranging study of the oral JAK inhibitor tofacitinib (CP-690,550) or adalimumab monotherapy versus placebo in patients with active rheumatoid arthritis with an inadequate response to disease-modifying antirheumatic drugs

(2011) Roy Fleischmann et al.   ARTHRITIS AND RHEUMATISM

Efficacy and safety of the human anti-IL-1beta monoclonal antibody canakinumab in rheumatoid arthritis: results of a 12-week, phase II, dose-finding study

(2011) Rieke Alten et al.   BMC MUSCULOSKELETAL DISORDERS

Certolizumab pegol for the treatment of rheumatoid arthritis

(2011) Sarah Horton et al.   EXPERT OPINION ON BIOLOGICAL THERAPY

Adalimumab for induction of clinical remission in moderately to severely active ulcerative colitis: results of a randomised controlled trial

(2011) W. Reinisch et al.   GUT

Development of Antidrug Antibodies Against Adalimumab and Association With Disease Activity and Treatment Failure During Long-term Follow-up

(2011) Geertje M. Bartelds   JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION

Integrated safety in tocilizumab clinical trials

(2011) Michael H Schiff et al.   ARTHRITIS RESEARCH & THERAPY

Ofatumumab, a human anti-CD20 monoclonal antibody, for treatment of rheumatoid arthritis with an inadequate response to one or more disease-modifying antirheumatic drugs: Results of a randomized, double-blind, placebo-controlled, phase I/II study

(2010) Mikkel Østergaard et al.   ARTHRITIS AND RHEUMATISM

2010 Rheumatoid arthritis classification criteria: An American College of Rheumatology/European League Against Rheumatism collaborative initiative

(2010) Daniel Aletaha et al.   ARTHRITIS AND RHEUMATISM

Abatacept for Rheumatoid Arthritis: A Cochrane Systematic Review

(2010) L. J. MAXWELL et al.   JOURNAL OF RHEUMATOLOGY

Effects of AIN457, a Fully Human Antibody to Interleukin-17A, on Psoriasis, Rheumatoid Arthritis, and Uveitis

(2010) W. Hueber et al.   Science Translational Medicine

Rilonacept-CAPS and Beyond

(2009) Neil Stahl et al.   Annals of the New York Academy of Sciences

Drug-specific risk of tuberculosis in patients with rheumatoid arthritis treated with anti-TNF therapy: results from the British Society for Rheumatology Biologics Register (BSRBR)

(2009) W. G. Dixon et al.   ANNALS OF THE RHEUMATIC DISEASES

The dynamics of macrophage lineage populations in inflammatory and autoimmune diseases

(2009) John A. Hamilton et al.   ARTHRITIS AND RHEUMATISM

Risk of tuberculosis is higher with anti-tumor necrosis factor monoclonal antibody therapy than with soluble tumor necrosis factor receptor therapy: The three-year prospective french research axed on tolerance of biotherapies registry

(2009) F. Tubach et al.   ARTHRITIS AND RHEUMATISM

Effectiveness and safety of etanercept in subjects with RA who have failed infliximab therapy: 16-week, open-label, observational study

(2009) Clifton O. Bingham et al.   CURRENT MEDICAL RESEARCH AND OPINION

Use of biofluorescence imaging to compare the distribution of certolizumab pegol, adalimumab, and infliximab in the inflamed paws of mice with collagen-induced arthritis

(2009) Roger Palframan et al.   JOURNAL OF IMMUNOLOGICAL METHODS

Anakinra for Rheumatoid Arthritis: A Systematic Review

(2009) M. MERTENS et al.   JOURNAL OF RHEUMATOLOGY

Golimumab in patients with active rheumatoid arthritis after treatment with tumour necrosis factor α inhibitors (GO-AFTER study): a multicentre, randomised, double-blind, placebo-controlled, phase III trial

(2009) Josef S Smolen et al.   LANCET

Sarcoid-like granulomatosis in patients treated with tumor necrosis factor blockers: 10 cases

(2009) C. I. Daien et al.   RHEUMATOLOGY

Ocrelizumab, a humanized anti-CD20 monoclonal antibody, in the treatment of patients with rheumatoid arthritis: A phase I/II randomized, blinded, placebo-controlled, dose-ranging study

(2008) Mark C. Genovese et al.   ARTHRITIS AND RHEUMATISM

Denosumab treatment effects on structural damage, bone mineral density, and bone turnover in rheumatoid arthritis: A twelve-month, multicenter, randomized, double-blind, placebo-controlled, phase II clinical trial

(2008) Stanley B. Cohen et al.   ARTHRITIS AND RHEUMATISM

Psoriatic skin lesions induced by tumor necrosis factor antagonist therapy: A literature review and potential mechanisms of action

(2008) Angelique N. Collamer et al.   ARTHRITIS AND RHEUMATISM

Th17 cells in human disease

(2008) Laura A. Tesmer et al.   IMMUNOLOGICAL REVIEWS

Efficacy and safety of abatacept or infliximab vs placebo in ATTEST: a phase III, multi-centre, randomised, double-blind, placebo-controlled study in patients with rheumatoid arthritis and an inadequate response to methotrexate

(2007) M Schiff et al.   ANNALS OF THE RHEUMATIC DISEASES

Tumor necrosis factor antagonist mechanisms of action: A comprehensive review

(2007) Daniel Tracey et al.   PHARMACOLOGY & THERAPEUTICS